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Abstract

IDENTIFYING FUNCTIONAL VARIATION IN SCHIZOPHRENIA GWAS LOCI BY
POOLED SEQUENCING
Erik Kristen Loken, B.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2014
Director: Brien P. Riley, Ph.D.
Associate Professor, Departments of Psychiatry and Human and Molecular Genetics
Schizophrenia demonstrates high heritability in part accounted for by common simple
nucleotide variants (SNV), rare copy number variants (CNV) and, most recently, rare SNVs
Although heritability explained by rare SNVs and CNVs is small compared to that explained by
common SNVs, rare SNVs in functional sequences may identify specific disease mechanisms.
However, current exome methods do not capture a large proportion of potentially functional
bases where rare variation may impact disease risk: as much as two-thirds of conserved
sequences lie outside the exome in non-coding regions of cross-species evolutionary constraint.
We reasoned that the candidate loci from the Psychiatric Genomics Consortium Phase 1 (PGC-1)
schizophrenia study represent good target loci to test for the impact of rare SNVs in non-coding
constrained regions. We developed custom reagents to capture mammalian constrained noncoding regions, exons, and 5’- and 3’-untranslated regions (UTRs) in the 12 PGC-1 loci for

pooled sequencing in 912 cases and 936 controls. Compared to our coding targets, our noncoding
targets contain substantially more highly conserved bases (46,412 vs. 31,609) and variants (390
vs. 193). Using C-alpha to detect excess variance due to aggregate risk increasing or decreasing
rare SNV effects, we identified signals attributable to alleles with MAF < 0.1% in both coding
sequences and in functional non-coding sequences, including variants within ENCODE
transcription factor binding sites, DNase hypersensitive regions, and histone modification sites in
neuronal cell lines. We also observed significant excess risk-altering variation in the CUB
domain of CSMD1, a gene expressed in the developing central nervous system. These results
support the hypothesis that common and rare variants in the same loci contribute to
schizophrenia risk, but highlight the need to expand capture strategies in order to detect traitrelevant sequence variation in a broader set of functional sequences.

Introduction

Relevant Background
Schizophrenia is an idiopathic, complex mental disorder with a lifetime risk of 0.4%
(Lichtenstein et al., 2006; Saha, Chant, Welham, & McGrath, 2005). The onset of the disease is
typically the early to mid-twenties for males and late twenties for females and can present either
acutely with onset of a psychotic episode or with a longer prodromal phase. Schizophrenia as a
syndrome was first described as “dementia praecox” by Emil Kraepelin (Kraepelin, 1899). He
was the first to recognize the disease as separate from bipolar disorder or, as he called it, manicdepression. To Kraepelin, the negative symptoms, those that reflect a loss of normal functions,
including avolition, anhedonia, alogia, and blunted affect were the most relevant in
distinguishing schizophrenia. Now the positive symptoms, those that reflect an excess or
distortion of normal functions, including delusions, hallucinations, and disorganized speech, are
given far more weight. Avolition describes the lack of initiation in goal-directed behavior,
anhedonia is the lack of pleasure, alogia is the lack of fluency of thought and speech and blunted
affect is a reduction in the range and intensity of emotional expression. Delusions are distortions
of inferential thinking, hallucinations are distortions in perceptions and disorganized speech is a
distortion in language. According to the DSM-5 (A. P. A. American Psychiatric Association,
American Psychiatric Association D. S. M. Task Force, 2013), at least one positive symptom
must be present during a one-month period in addition to another positive symptom, catatonia, or
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negative symptom and the disturbance must be present for six months to diagnose schizophrenia.
Previously, the DSM-IV (A. P. A. American Psychiatric Association, American Psychiatric
Association Task Force on D. S. M. I. V., 2000) included five subtypes (paranoid, disorganized,
catatonic, undifferentiated and residual), but as of the DSM-5 these subtypes are not included.
Schizophrenia has a very high heritability, established as 0.81 in twins (Sullivan,
Kendler, & Neale, 2003) and 0.64 in a study of the Swedish population (Lichtenstein et al.,
2009). Further evidence of its heritability is a strong sibling recurrence risk of 8.55 (Lichtenstein
et al., 2006). Schizophrenia has a high genetic correlation with bipolar disorder (0.68), major
depressive disorder (0.43), and a lower genetic correlation with autism spectrum disorder (0.16)
(Lee et al., 2013). These correlations have been supported by data from more recent studies
detailed in this chapter in the form of joint and independent associations of loci with multiple
psychiatric disorders.
Despite the evidence for high heritability, monozygotic twin (MZ) concordance is only
48%, suggesting that genetic risk factors do not entirely explain schizophrenia and that
environmental risk factors are also important (Onstad, Skre, Torgersen, & Kringlen, 1991). The
number of environmental and non-genetic risk factors studied and found contributing to
schizophrenia is numerous, including paternal age (Petersen, Mortensen, & Pedersen, 2011),
season of birth (J. J. McGrath & Welham, 1999), famine (St Clair et al., 2005), cannabis use
(Hill, 2014), urban birth (J. McGrath & Scott, 2006), migration (Cantor-Graae & Selten, 2005),
and prenatal infection (Khandaker, Zimbron, Lewis, & Jones, 2013). A meta-analysis of the
prenatal maternal influenza infection literature has found no evidence of contributions to
schizophrenia risk from the 1957 pandemic of influenza (Selten, Frissen, Lensvelt-Mulders, &
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Morgan, 2010), but the prenatal infections Toxoplasma gondii and herpes simplex virus (HSV-2)
show some effect (Brown & Derkits, 2010; Khandaker et al., 2013).
Environmental risk factors are divided into common environmental factors to which both
twins are exposed, and unique environmental factors to which twins are independently exposed.
Common environmental risks are estimated by twin studies to represent 11% of the variance for
schizophrenia while unique environmental factors are estimated to represent the remainder of the
variance, 8% (Sullivan et al., 2003). Paternal age, season of birth, famine, urban birth and
prenatal infection represent common environmental risk factors. Cannabis use and migration,
may represent unique environmental risk factors. The examples listed that would contribute to
the relatively low twin concordance are cannabis use, migration, measurement error (included in
unique environment), and unknown unique environmental risk factors. Future studies
investigating the environmental causes of schizophrenia will use prospective birth cohort studies
instead of ecological and retrospective designs. By incorporating genotypes with environmental
data, it is possible significant gene by environment interaction could be found (Brown, 2011),
explaining low MZ concordance.

Linkage and Candidate Genes
These findings have inspired a large molecular genetics effort to identify the source of
heritability. Pedigree analysis showed no evidence for one-locus mendelian transmission of
schizophrenia (Elston, Namboodiri, Spence, & Rainer, 1978). This lack of evidence for a single
causal locus and the swift drop in recurrence risk from monozygotic twins (52.1) to siblings (8.6)
and offspring (10), suggested a multilocus model for heritability (Risch, 1990). This led to a
large number of linkage studies searching for what investigators thought would be a few loci
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responsible for schizophrenia. Early studies found no loci in linkage with schizophrenia (Kendler
& Diehl, 1993), but later studies point to weak linkage at 22q12-q13, 8p22-p21, 6p24-p22,
13q14.1-q32, 5q21-q31, 10p15-p11, 6q21-q22, 15q13-q14 and 20q11-q22 (McGuffin, Tandon,
& Corsico, 2003) (Riley, 2004) with minimal agreement between studies. Positional loci
suggested from these findings include NRG1, G72, DAAO, DTNBP1, and COMT, and an
additional linkage discovery that was named Disrupted-In-Schizophrenia-I (DISC1) (Ishizuka,
Paek, Kamiya, & Sawa, 2006) (Chubb, Bradshaw, Soares, Porteous, & Millar, 2008). The
estimated effect sizes from linkage that were found were relatively small, and the positional
candidate loci did not produce any significant variants on follow-up (Kirov, O'Donovan, &
Owen, 2005). For the sample sizes collected, the lack of strong linkage in schizophrenia suggests
that no locus existed with a recurrence risk > 3 (Owen, Craddock, & O'Donovan, 2005).

Theoretical Candidate Genes
Theoretical candidate genes for schizophrenia such as the dopamine receptors DRD3 and
DRD2, the serotonergic receptor HTR2A, and the glutamatergic gene GRM3 have been studied
and proposed as candidate genes because of their role in systems thought to be perturbed in
schizophrenia, but until recently there has been a complete lack of any robust findings from these
candidates (Kirov et al., 2005). More recently, evidence for theoretical candidate loci impacting
schizophrenia has been found. The second phase of the Psychiatric Genomics consortium (PGC2) genome-wide association study (GWAS) (S. W. G. o. t. P. G. Consortium, 2014), a large
study of 36,989 schizophrenia cases and 113,075 controls, found associations in DRD2, the
dopamine receptor target for antipsychotic drugs, and genes involved in glutamatergic
neurotransmission (GRM3, GRIN2A, SRR, GRIA1). Genes (GRM5, PPEF2, and LRP1B) that
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encode protein products associated with the glutamate receptor N-methyl-D-aspartate receptor
(NMDAR) have been found to have rare protein-altering variants in five schizophrenia pedigrees
(Timms et al., 2013)

Genome-Wide Association Studies
An early GWAS (Stefansson et al., 2009) of 2,663 schizophrenia cases and 13,498
controls found associations in the Major Histocompatibility Complex (MHC) of chromosome 6,
and the genes TCF4 and NRGN. Compared to other GWAS at these sample sizes, the results
were not very impressive (W. T. C. C. Consortium, 2007). An additional study (Purcell et al.,
2009) of 3,322 schizophrenia cases and 3,587 controls found associations for MYO18B, the
MHC region, ZNF804A, and six imputed human leukocyte antigen (HLA) alleles. The MHC
region included over 450 single nucleotide polymorphisms (SNPs) across several Megabases
(Mb). To analyze the GWAS signal for polygenicity, the authors summed odds-ratio (OR)
weighted allele counts of independent variants per individual, and compared the scores of cases
and controls. The aggregation of the signals for a great number of alleles of a small and neutral
effect explained 3% of the variance for schizophrenia. This result indicated that although few
loci had been observed through GWAS, causal variants were distributed throughout the genome
at lower effect sizes, and that increasing sample size could lead to the discovery of more loci.
The most successful published efforts so far have been the very large collaborative efforts of the
Psychiatric Genomics Consortium (PGC) GWAS to analyze large schizophrenia samples (Ripke
S, 2011) (Ripke et al., 2013). The PGC-1 schizophrenia GWAS of 9,394 cases and 12,462
controls identified 8 loci by peak significant SNPs, MIR137, PCGEM1, TRIM26, CSMD1,
MMP16, CNNM2-NT5C2, STT3A and CCDC68-TCF4 (hyphens included for loci with multiple
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genes). In addition to these loci the authors combined the schizophrenia cases with 16,374
bipolar disorder cases for a joint association study, finding ANK3, CACNA1C and ITIH3-ITIH4
associated with the combined disorders. SNPs were intragenic to their loci except for PCGEM1
(343 kb distance to nearest gene), MMP16 (421 kb), STT3A (1 kb) and CCDC68 (126 kb). A
peak significant SNP was intragenic to TCF4, a locus previously implicated in schizophrenia
(Steinberg et al., 2011). MIR137 was a novel and interesting result for schizophrenia in that it
encodes a microRNA (miRNA) that is predicted to target four of the other significant loci in the
study (TCF4, CACNA1C, CSMD1 and C10orf26). An additional study (Ripke et al., 2013),
combining PGC-1 with a Swedish national sample of 5,001 cases and 6,243 controls, expanded
the significant loci to 22, of which 13 were new. This study represents the most up-to-date peerreviewed results for common variation in schizophrenia. Using Genome-wide Complex Trait
Analysis (GCTA) (Yang, Lee, Goddard, & Visscher, 2011), a method to estimate the variance in
liability explained by all SNPs, researchers estimated SNP heritability to be 0.27, assuming a
population risk of 0.004 (Lichtenstein et al., 2006), and 0.33, assuming a population risk of 0.01.
The upper bound for schizophrenia heritability is 0.64 to 0.81, based on population and twin
evidence, and the lower bound for schizophrenia SNP heritability is 0.27 to 0.33, using a
population risk of 0.004 or 0.01. These results suggest that between one-third and one-half of
schizophrenia heritability comes from common SNPs and at least half of the heritability of
schizophrenia is left to be explained by other sources. A number of sources of this additional
heritability have been suggested and studied intensively, including rare SNPs/indels (SNVs)
identified by sequencing, CNVs identified directly from array comparative genomic
hybridization (aCGH) or indirectly from intensity data on GWAS arrays, gene-environment
interactions (GxE) (Iyegbe, Campbell, Butler, Ajnakina, & Sham, 2014; Maric & Svrakic, 2012;
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Modinos et al., 2013; Svrakic, Zorumski, Svrakic, Zwir, & Cloninger, 2013), and gene-gene
interactions (GxG or epistasis) (Chiesa et al., 2013; Nicodemus et al., 2010; Won et al., 2014).
The PGC-2 schizophrenia study (S. W. G. o. t. P. G. Consortium, 2014) is currently in
submission. It expands the samples size to 36,989 schizophrenia cases and 113,075 controls.
This is the largest molecular genetics study of schizophrenia or any other neuropsychiatric
disorder and it found 108 distinct associated loci, 83 of which were not previously observed in
schizophrenia. It is the first to strongly implicate DRD2, the target of antipsychotic
pharmaceuticals used to treat schizophrenia. It also implicates genes involved in glutamatergic
neurotransmission (GRM3, GRIN2A, SRR, GRIA1). More associations (CACNAB2 and
CACNA1I) in voltage gated calcium channel subunits were observed including CACNA1C.
Associations in active enhancers from 56 different tissues and cell lines showed significant
enrichment not only in brain, but also tissues with immune functions such as the CD19 and
CD20 B-lymphocyte cell lines.

Copy Number Variants
Rare variants implicated in schizophrenia first came in the form of CNVs (Rees et al.,
2014) (Walsh et al., 2008). Many of these studies were not measuring heritable contributions
from CNVs because they focused on de novo mutations (Malhotra et al., 2011) (Stefansson et al.,
2008). 22q11.2 deletion syndrome, also known as velocardiofacial syndrome or DiGeorge
syndrome was found to be primarily de novo in newly diagnosed patients, with 90% of the
deletions being de novo and 10% being inherited (Bassett, Marshall, Lionel, Chow, & Scherer,
2008). Some standing CNVs affecting schizophrenia, and inherited 2p16.3 deletion affecting
NRXN1(Kirov et al., 2008), duplications of 16p13.1 (Ingason et al., 2011), and duplications of
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16p11.2 (McCarthy et al., 2009), have been discovered. Heritable CNVs show minor allele
frequency (MAF) ranges of 0.30% in cases for the 16p11.2 duplication compared to 0.03% in
controls (8.4 OR) and 0.12% in cases for the 16p13.1 duplication compared to 0.04% in controls
(3.27 OR). Examples of replicated signals in deletions show MAF between 0.23-0.32% for
1q21.1, with an OR ranging 6.6-14.8, and 0.17-0.3% MAF for 15q13.3, with an OR ranging
11.5-17.9 (Sebat, Levy, & McCarthy, 2009). These loci are nonspecific risk factors for other
disorders, such as developmental delay and congenital malformations for 1q21.1 and generalized
epilepsy and mental retardation for 15q13.3 (Sebat et al., 2009). In addition, 16p11.2 deletions
are more common in autism and developmental delay (0.78% MAF, OR 38.7) while not at all
more common in schizophrenia. CNVs have low MAFs, high ORs, and pleiotropic effects. The
presence of CNVs impacting schizophrenia risk in addition to GWAS data support a complex
genetic architecture with rare and common variation.

Exome Studies
The first exome studies of schizophrenia were published in the last few years. One of the
first found an elevated de novo mutation rate in 14 schizophrenia trios (Girard et al., 2011).
Another published concurrently a de novo design of 53 case and 22 control trios, identified 40 de
novo mutations in cases, one of which was in DGCR2, a gene located in the 22q11.2 DiGeorge
Syndrome locus (B. Xu et al., 2011). Using rare inherited variants for comparison, the authors
observed an excess of non-synonymous variants that were de novo. This study was later
expanded to 231 schizophrenia trios and 34 control trios (B. Xu et al., 2012). The excess signal
from de novo nonsynonymous SNVs was replicated and these variants were more enriched in
genes with greater prenatal expression. A study of 166 cases and 307 controls (Need et al., 2012)
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with a strategy using a follow-up cohort of 2,756 cases and 1,932 controls for further testing
found no significantly associated SNVs. With the relatively small sample size, there was only
power to detect variants at 1% MAF with a relative risk of 6 for a nominal association leading to
follow-up. One exome study of five large schizophrenia pedigrees (Timms et al., 2013) found
rare protein-altering variants implicating glutamatergic neurotransmission. Protein-altering
variants from one of three genes, GRM5, PPEF2, and LRP1B, whose protein products are
associated with NMDAR, were discovered in all five pedigrees. A recent exome study
(McCarthy et al., 2014) of 57 sporadic and familial schizophrenia trios found a 3.5-fold increase
of de novo mutations in the sporadic probands compared to the familial probands. These de novo
mutations were found in excess in genes with a high estimated probability of haploinsufficiency.
An overlap of loci with de novo mutations was observed with autism (AUTS2, CHD8 and
MECP2) and intellectual disability (HUWE1 and TRAPPC9).
A new round of larger exome studies has been published for schizophrenia. The first is a
study of de novo mutations from trios (Fromer et al., 2014). The study authors acknowledge that
they are using the same study design as many de novo CNV trio studies, but with exome
sequencing they now have the resolution to identify single base de novo mutations that impact
schizophrenia. Using data from 623 exomes from schizophrenia trios and 731 controls from
published data sets, they did not identify any excess rate of de novo point mutations in
schizophrenia probands. They were able to identify enrichment of nonsynonymous de novo
mutations in genesets with independent evidence for involvement in schizophrenia. They also
found an enrichment of loss-of-function mutations in genes identified in autism and intellectual
disability studies of de novo variants. Certain genesets also had an enrichment of
nonsynonymous mutations, most notably those encoding components of the activity-regulated
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cytoskeleton-associated protein (ARC) complex, the NMDAR complex, and genes regulated by
the fragile X mental retardation protein (FMRP). The authors targeted the first two sets for
analysis because of the presence of de novo CNVs in the ARC and NMDAR complexes (Kirov
et al., 2012). In addition to nonsynonymous mutations, the ARC and NMDAR complexes were
also significantly enriched for loss-of-function de novo mutations in cases. FMRP and its targets
are implicated by de novo mutations in autism (Iossifov et al., 2012) that specifically impact
these brain-expressed genes related to synaptic function (Darnell et al., 2011). Because of its
connection to autism and synaptic function, the authors hypothesized that de novo mutations
would also be a factor for schizophrenia. They observed that nonsynonymous de novo mutations
in FMRP target genes were significantly enriched in cases. There was also an enrichment of lossof-function de novo mutations in genes with excess loss-of-function de novo mutations found in
autism and intellectual disability studies. The genes with loss-of-function de novo mutations in
autism were also enriched for nonsynonymous de novo mutations in schizophrenia.
The other major exome study published in the same issue of Nature was a case-control
study of exomes sequences from 2,536 schizophrenia cases and 2,543 controls (Purcell et al.,
2014). The authors of this study and the trio study shared data and Purcell et al. were able to
confirm the signal in the ARC complex for disruptive (nonsense, essential splice site and
frameshift) singletons and < 0.5% MAF variants. The NMDAR complex association from
Fromer et al. was not replicated. The genes implicated in the de novo SNV studies had an
enrichment of < 0.5% MAF distruptive variation. Focusing on a composite geneset of loci
previously implicated in schizophrenia by GWAS (Ripke et al., 2013), CNV(Kirov et al., 2012)
(Sullivan, Daly, & O'Donovan, 2012), and de novo SNV studies (Girard et al., 2011; Purcell et
al., 2014; B. Xu et al., 2012), the authors observed a significant enrichment of singleton and <
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0.5% MAF disruptive variation in case samples. A significant enrichment of.< 0.1% MAF case
variation was observed when including missense variants predicted to be damaging by multiple
prediction algorithms in the test set. There was an enrichment of singleton disruptive variants for
voltage-gate calcium ion channel genes, especially in CACNA1C, which was implicated as a
joint bipolar disorder and schizophrenia risk locus in the PGC-1 analysis (Ripke S, 2011).
Expanding their analysis to crossover points with autism studies the authors observed enrichment
of case disruptive and nonsynonymous alleles in FMRP targets identified from mouse brain
(Darnell et al., 2011) for < 0.1% MAF variation. FMRP targets identified from human kidney
(Ascano et al., 2012) did not contain any case enrichment of disruptive variants, suggesting that
for these FMRP targets the location of the targeting to the brain across species is more
meaningful for testing than the targets across tissues but from the same species.
The exome studies build upon the previous GWAS and CNV studies, but are not
definitive for the impact of rare variation in schizophrenia. Overall, the results point towards
schizophrenia genes having brain functions, specifically synaptic network functions. There is
overlap between bipolar disorder and schizophrenia both phenotypically and genotypically.
Shared SNP-based coheritability for the two disorders is estimated to be 0.68 (Lee et al., 2013)
and certain specific genes, such as the jointly associated voltage-gated calcium ion channel
CACNA1C (Ripke S, 2011), have now been observed as independent associations for bipolar
disorder (Ferreira et al., 2008) and schizophrenia (S. W. G. o. t. P. G. Consortium, 2014). In both
the de novo SNV and the case-control exome studies, FMRP targets were identified as a source
of rare variant enrichment, risk, and overlap with autism. The case-control exome study did not
find enrichment in the common SNP loci from the GWAS studies. The test did have a suggestive
p-value for disruptive MAF < 0.5% variants (0.0037) but this did not meet the significance
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threshold based on multiple testing. The lack of rare variants impacting the common variant loci
could be due to the relatively small samples size from the exome study, 2,536 exome cases
compared to a meta analysis of 9,394 PGC-1 cases, and 5,001 Swedish cases.
A final interesting component of the exome studies is their estimation of the variance of
schizophrenia risk explained by polygene scores in an overlapping sample of 5,079 individuals
due to SNPs (5.7%), rare CNVs (0.2%), and disruptive mutations (0.4%). The authors note that
the rare CNVs and disruptive mutations explain an order of magnitude less variance that the
SNPs. The authors admit that these estimates represent a conservative lower bound for the true
estimates, as the disruptive mutations are only from the composite set (see above) which
represents about 10% of the genome (~2,500 genes). Including the rest of the genome, more
samples, and potentially a more relaxed set of variants beyond disruptive variation (nonsense,
essential splice site and frameshift), should increase the variance explained by rare SNVs. Rare
variation is observed less frequently than common variation, requiring larger sample sizes and
effect sizes to detect associations. Samples sizes for exome studies so far have been an order of
magnitude lower than for GWAS and exome sequencing in schizophrenia has yet to obtain a
statistically significant signal for either a single allele or for alleles aggregated across a single
gene. Increasing sample size to approximately the level now available in the largest GWAS of
schizophrenia seems necessary to provide the power needed for identification of either single
loci enriched for variation in cases or specific rare variants associated with schizophrenia.

Non-coding Variation
It is important to consider why the exome and not the genome is the current standard for
large sample sequencing studies. The cost for genome sequencing has dropped rapidly since
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2001, but the rate of decrease has been less dramatic in the last two years with the estimated cost
at about $4,008 as of January 2014 (Figure 1) (Wetterstrand, 2014). Exome sequencing using
target capture (Asan et al., 2011) is far cheaper with recent rates quoted as low as $500 per
exome (Perkel, 2013). Investigators reason that the most important part of the genome in which
to look for variation are the coding regions. Some exome capture reagents also target UTRs and
miRNA.

Figure 1: The cost of whole genome sequencing over the years

These approaches are missing potentially important target regions. A study of human
evolutionary constraint by comparison of 29 mammalian genomes observed that at least 5% of
the human genome is under purifying selection (Lindblad-Toh et al., 2011). Selection implies
functionality of the underlying sequence, only 1.5% of which is coding in the human genome. As
13

much as two-thirds of constrained, likely functional sequences are non-coding and are therefore
completely missed by exome studies. For a complex genetic disorder like schizophrenia with no
observed single rare coding changes associated with disease, this could represent a critical
amount of contributing variation. The Encyclopedia of DNA Elements (ENCODE) (Rosenbloom
et al., 2013) study is a collaborative study with the goal of creating a complete catalog of
functional elements for the human genome. As of 2013 it consists of 2,886 experiments from
multiple sites made public by the University of California for download and use on its genome
browser (Kent et al., 2002). The ENCODE project has identified regions in the human genome
that include sites of modifications to histones which effectively increase or decrease local gene
expression, sensitivity to DNase-I, indicating open chromatin and potential for transcription, and
transcription factor binding sites. Data have been included in the ENCODE project from many
cell lines, including those originating from glia and neurons that are most useful for the study of
brain disorders like schizophrenia. Histone modifications sites, DNase-I hypersensitive sites, and
transcription factor binding sites occupy largely non-coding regions not included in a traditional
exome capture. Current capture reagents (even those including UTRs) do not include these
potentially important functional sequences and are likely to be missing an important functional
component of the genome.

Common Variant Loci
A great amount of effort in sample collection, planning, and funding went into current
exome studies. Two strategies can be used to reduce the scope of work and expense of
identifying rare causal variation associated with disease: pooled sequencing (Futschik &
Schlotterer, 2010) and targeting of smaller regions than the exome. In the pooled sequencing
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approach, groups of samples are combined in equimolar amounts and sequenced as one sample.
This allows library preparation costs, a significant component of sequencing costs, to be reduced
by the factor of the pool size. Common variant loci have been hypothesized to also contain rare
associated variation. This has been shown in inflammatory bowel disease (IBD) (Rivas et al.,
2011), which includes both Crohn’s disease and ulcerative colitis, autoimmune diseases of the
whole digestive system and the colon, respectively. Rivas et al. used pooled targeted sequencing
of 56 genes from common variant loci identified in GWAS to identify potentially causal rare
variation in 350 cases and 350 controls. They identified 70 rare variants that cause a change to
the proteins implicated in GWAS of IBD. This study strategy allows low cost sequencing of a
reduced target area. Low cost sequencing allows a greater sample size to be sequenced and
combined with the reduced target area, increasing the power of the study to detect effects of rare
variation. Rivas et al. identified multiple rare variants through follow-up genotyping in 16,054
Crohn’s disease cases, 12,153 ulcerative colitis cases, and 17,575 healthy controls, some
protective and some damaging. The observation of protective rare variant for a disease is not
isolated to IBD, having been observed in coronary heart disease (Cohen, Boerwinkle, Mosley, &
Hobbs, 2006) and plasma low-density lipoprotein levels (Cohen, Pertsemlidis, et al., 2006).

Aims
Taking this information in aggregate, it is clear that much of the heritability is from
unknown sources (Manolio et al., 2009) (Lee, Wray, Goddard, & Visscher, 2011) and the large
majority of heritability that is measurable is polygenic and spread throughout the genome at
common and rare allele frequencies. The common variant loci from the PGC-1 schizophrenia
study very likely represent the best candidate loci for unbiased follow-up in a targeted rare
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variant study. Unlike the IBD study, we hypothesized that by including relevant non-coding
variation identified in the study of 29 mammals (Lindblad-Toh et al., 2011) we would increase
our functional target substantially compared to the coding sequence of these loci alone. We had
access to 912 cases in our Irish Case-Control Study of Schizophrenia (ICCSS) and 936
unscreened Irish controls from the Trinity Biobank for the study. We aimed to identify functional
rare variation in the coding and non-coding sequences of the top schizophrenia common variant
loci. To accomplish this goal, we adapted the pooled, targeted sequencing approach from Rivas
et al. to reduce costs by focusing the target, while still maximizing sample size. Instead of using
PCR amplification of exons, we used in-solution hybridization capture (Bansal, Tewhey,
Leproust, & Schork, 2011) to reduce sample processing load and still be able to sequence many
different targets within our loci. For analysis, we not only used Burden tests (Price et al., 2010),
which allow for directionally specific aggregate effects, but also C-alpha (Neale et al., 2011), a
test which measures bidirectional aggregate effects. This allows us to take advantage of the
possibility of a similar observation in schizophrenia of not only damaging variants but protective
variants like in IBD, coronary heart disease (Cohen, Boerwinkle, et al., 2006), and low-density
lipoprotein levels (Cohen, Pertsemlidis, et al., 2006). Using all these techniques and all this
knowledge, we aimed to detect rare variation impacting schizophrenia in common variant loci
not only in coding regions, but also the two-thirds of potentially functional variation that is noncoding with goals of improving the understanding of schizophrenia genetics in its top loci and
schizophrenia genetics, generally.
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Methods

Sample Information
We selected 912 schizophrenia cases from the ICCSS and 936 unscreened Irish controls
from the Trinity Biobank for sequencing. The ICCSS was collected by Kenneth Kendler of the
Virginia Commonwealth University from 1999 to 2003 (Riley et al., 2010). Affected subjects
were selected from inpatient and outpatient psychiatric facilities in the Republic of Ireland and
Northern Ireland. Subjects were eligible for inclusion if they had a diagnosis of schizophrenia or
poor outcome schizoaffective disorder by DSM-III-R criteria. Diagnoses were confirmed by a
blind expert diagnostic review and subjects must have reported all four grandparents as being
born in Ireland or the United Kingdom. The use of DSM-III-R maintained consistency with
previous DSM-III-R era collections done by the group. Each proband completed a personal
interview with a detailed family history. The control subjects are blood donors from the Trinity
Biobank in Dublin. Although not given a formal diagnostic interview, all control subjects deny
any personal or family history of psychosis. The relatively low prevalence of schizophrenia
(~1%) makes these donors suitable controls. The ethnic homogeneity of the sample avoids
population stratification in our studies.

Target Capture
Agilent SureSelect Custom solution-based capture allows capture of custom designed
regions of the genome. The small size array allowing up to 500kb of sequence was ideal for our
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application. To define target intervals, we first examined linkage disequilibrium (LD) around
associated SNPs from the PGC results using Haploview and HapMap data version 3 release 27
from individuals of European descent, the Centre d'Etude du Polymorphisme Humain (CEPH)
sample of Utah residents with ancestry from northern and western Europe (CEU), and Tuscan
Italian (TSI) samples. The CEU and TSI samples were chosen to best approximate the PGC-1
sample composition with the available HapMap ethnicities. Pairwise markers > 500 kb apart
were ignored and individuals with > 50% missing genotypes were excluded. We included the
associated SNPs from the schizophrenia analysis and the joint schizophrenia and bipolar
association loci where bipolar and schizophrenia where analyzed as one phenotype (Table 1).
The schizophrenia study loci are MIR137, PCGEM1, TRIM26, CSMD1, MMP16, CNNM2,
NT5C2, STT3A, CCDC68, and TCF4. The joint targets are ITIH3/4, ANK3, and CACNA1C. The
target interval is defined as the region with R2 > 0.8 with the associated SNP. If the interval
overlaps part or all of one or more genes, then all exons and constrained sequence from those
genes were included in the target set. For several loci, the LD interval did not overlap any gene
(PCGEM, MMP16, CCDC68). The MMP16 region only contained the original associated SNP
from the PGC analysis. These three loci only contributed to 520 bp (base pairs) of constrained
regions total (Table 1). Because we were underpowered to detect association for the 3, we were
left with 9 out of the 12 loci for locus testing.
Within these regions we selected all coding and UTR sequences in addition to regions
from the 29 mammals paper (Lindblad-Toh et al., 2011) including human and primate
accelerated regions, regulatory motif instances, peaks indicating constraint structure in promoters
and, finally, SiPhy-omega and SiPhy-pi constrained regions with a logarithm of odds (LOD)
score requirement of at least 7.325 for inclusion to allow the best regions within the constrained
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sequence space of 500kb. These regions were then used to design a SureSelect custom capture
library consisting of 120 bp baits (Agilent Technologies, Santa Clara, CA) using SureDesign
software with moderate masking of repeats. The final Agilent SureSelect target capture design
included 84.5% of the non-coding regions that the 29 mammals study (Lindblad-Toh et al.,
2011) considered constrained at the 10% false discovery rate (FDR) level.

Locus
MIR137
PCGEM1
TRIM26
CSMD1
MMP16
CNNM2 & NT5C2
STT3A
CCDC68
TCF4
ITIH3/4
ANK3
CACNA1C
Totals

Table 1: GWAS loci target Intervals
Chr.
Association
1p21.3
SCH1
2q32.3
SCH
6p21-22
SCH
8p23.2
SCH
8q21.3
SCH
10q24
SCH
11q24.2
SCH
18q21.2
SCH
18q21.2
SCH
3p21.1
Joint2
10q21.2
Joint
12p13.33
Joint

Total Target
10232
140
3888
29399
1
26609
4846
379
67448
18640
43303
31821
236706

1

Schizophrenia association results. 2Results from joint bipolar and schizophrenia associations

Library Preparation and Sequencing
Samples were run on 1.5% agarose gels to check for the presence of high molecular
weight DNA. Only samples with high molecular weight DNA (lanes 1-9 and 11-18, Figure 2)
were included in this project; degraded samples (example in lane 10, Figure 2) were excluded.
Nanodrop spectrophotometry was used to confirm sample purity using a 260/280 ratio of 1.8 to
2.0. One round of PicoGreen (Life Technologies, Carlsbad, CA) dsDNA quantitation was
performed to measure the concentration double stranded DNA only. After adjusting sample
concentrations to 50 ng/µL of dsDNA we performed a second round of PicoGreen quantitation
and adjusted concentrations to 23 ng/µL, the recommended shearing concentration for library
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preparation. We then performed a third round of PicoGreen quantitation to determine the precise
individual sample concentrations for equimolar pooling.

Figure 2: Representative gel results for quality control of cases and controls. Here are 18 controls one of which is
degraded (lane 10) and the rest of which contain high molecular weight DNA. The sample from lane 10 was too degraded
to include in the study.

We constructed pools of 24 case or 24 control subjects. Twenty-four samples per pool
were ideal for several reasons. First, Illumina, our chosen sequencing platform has a nominal 1%
error rate. Therefore 50 samples or 100 chromosomes would be the maximum allowable per pool
to still allow detection of a singleton allele in the pool at or above the error rate. Reducing pool
size to 24 samples (or 48 chromosomes) doubles the signal expected from a singleton allele and
substantially improves detection of singleton alleles over errors in the pool. Second, we had
reagents for 96 pools based on kit sizes from Agilent, which gave a minimum size of 20 samples
per pool to include all selected subjects. Finally, 4 sets of 24 samples fit on a standard 96-well
plate, which increases workflow efficiency and allows for spare capture reagents. We pooled
each set of 24 case or control samples into equimolar pools basing the exact volume on the final
PicoGreen concentration readings using robotic liquid handling to maximize accuracy. The final
study sample included 38 case and 39 controls pools.
We sheared 130 µL from each pool stock using the Covaris S2 instrument (Covaris,
Woburn, MA) with a duty cycle of 10%, intensity of 5, 200 cycles per burst and the frequency

20

sweeping mode for 6 cycles of 60 seconds each to get a target peak base pair size of 150 to 200
bp. We followed this with purification of the pool using Agencourt AMPure XP beads (Beckman
Coulter Inc., Pasadena, CA). Every sheared pools size distribution was assessed using the
Agilent 2100 Bioanalyzer with a DNA 1000 chip (see representative trace, Figure 3). Shearing
leaves damaged ends to the double stranded DNA, so we followed this step with end repair using
T4 DNA polymerase, Klenow DNA Polymerase, T4 Polynucleotide Kinase, and reagents from
the SureSelect Library Prep Kit, followed by an additional AMPure XP purification. We added A
bases to the 3’ end of the fragments for each pool using exo(-) Klenow fragment, dATP, and
reagents from the SureSelect Library Prep Kit followed by an AMPure XP purification. We then
ligated adapters to the pool fragments using T4 DNA Ligase and SureSelect Library Prep Kit
reagents followed by AMPure XP purification. To produce enough library for hybridization we
amplified the libraries for 5 cycles of PCR using Herculase II Fusion DNA Polymerase and
SureSelect Library Prep Kit reagents. We then purified the pool libraries using AMPure XP and
measured concentration and quality using a DNA 1000 chip on the 2100 Bioanalayzer. We dried
the pools using a vacuum concentrator and reconstituted them with nuclease-free water at a
concentration of 220 ng/µL for hybridization.
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Figure 3: Representative trace of pool 56 after shearing using the Covaris S2. The peak is at 173 bp, between the targets
of 150 and 200.

We preformed target capture using solution hybridization of pool library fragments with
the 120 bp baits produced for the SureSelect Custom Capture. We denatured the concentrated
pool libraries and then combined them with hybridization buffers. We added index blocking
oligonucleotides to prevent index and adapter sequences from inhibiting hybridization between
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the baits and the target sequence. We incubated the final hybridization mixture for 24 hours at
65˚C with a heated lid at 105˚C.
We biotinylated the hybridization baits, allowing selective capture of bait-target hybrid
fragments using Dynabeads MyOne Streptavidin-coated T1 magnetic beads (Life Technologies,
Carlsbad, CA). We mixed the Streptavidin T1 beads with the hybridization mixture and allowed
it cool to room temperature while mixing for 30 minutes on a rotator followed by two washes
using SureSelect Kit reagents. In the denaturation step of PCR, the library and bait disassociate
and the library fragments move into solution. This allowed us to perform PCR directly from the
beads in the PCR solution to amplify the library and add the index tags. We used Herculase II
Fusion DNA Polymerase and a random selection of 77 of the 96 Illumina PCR Primer Indexes
for the PCR reactions and we ran 16 cycles for each pool. We purified each pool using AMPure
XP, which conveniently removes the used Dynabeads MyOne Streptavidin-coated T1 magnetic
beads from solution, and analyzed for concentration and library quality using the DNA High
Sensitivity Chip on the Bioanalyzer (see representative trace, Figure 4).
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Figure 4: Representative trace of pool 56 after target capture and PCR. The peak is now above 300 bp, due to the addition
of the adapters and index tags to the library.

We performed qPCR on each pool using the QPCR NGS Library Quantification Kit
(Illumina, San Diego, CA) to measure the concentration of each pool for equimolar
megapooling. To test the accuracy of megapool construction, we used these concentrations to
make a test megapool of the post-capture library pools using robotic liquid handling and ran this
test megapool on an Illumina MiSeq 150 bp paired-end run at the VCU core lab. We aligned the
reads from this run using BWA (Li & Durbin, 2009) and we used the coverage results to adjust
the 77 individual pool concentrations one more time to construct the final equimolar megapool.

24

We sent the megapool to the VCU core lab for 103 bp paired-end sequencing on the Illumina
HiSeq 2500 where it was cross loaded onto 5 lanes of the flowcell.

Sequence Data Processing
After we received the raw reads from the core lab, we aligned the reads to the genome
using BWA version 0.7.0 (Li & Durbin, 2009). BWA uses the Burrows-Wheeler transformation
to allow quick alignment of the reads to the genome. We used the Genome Analysis Toolkit
(GATK) version 2.5 (DePristo et al., 2011) to do local realignment of reads to reduce
mismatches near indels. Each base in a sequencing experiment has a Phred quality score
indicating the probability the base call is an error according to the formula ! = −10!"#!" !
where P is the error probability and Q is the Phred score. The score is included as output from
the sequencing platform’s internal software and can be improved using covariates and alignment
information to recalibrate the scores. We performed base quality score recalibration using GATK
using read group, reported quality score, cycle (base position in read), and context (dinucleotide
and trinucleotide) to produce more accurate empirical quality scores for variant calling.

Variant Calling
We called variants from the finalized realigned and recalibrated sequence data using
CRISP (Bansal, 2010) (Comprehensive Read analysis for Identification of SNPs from Pooled
sequencing), a variant caller developed specifically for read data from pooled sequencing. CRISP
is able to call variants in pools by first comparing the allele count distribution across all the pools
in the experiment using contingency tables. It then evaluates the probability that multiple nonreference base calls at a locus are due to sequencing errors. To distinguish a sequencing error

25

from a real variant, it uses the distribution of alternate allele counts across the pools as a guide. If
the distribution is similar across the pools, this is more likely to reflect sequencing error.
Differences in the distribution of apparent allele counts across pools indicate varying allele
counts in the pool and support the existence of a true variant at the site. CRISP also takes the
sequencing error rate into account and computes a probability that a certain number of alternate
alleles would be present at a site given sequencing error alone. The lower this probability, the
greater the evidence for a true variant at the site. Finally, the number of chromosomes per pool is
!

considered to ensure that the alternate allele frequency does not deviate too far below !, where h
is the number of haplotypes in the pool. If the frequency of alternate base calls at a site is much
lower than expected using a binomial test, it is more likely that the signal represents sequencing
error.

Quality Control
We conducted all data processing and analyses in R version 3.0.2 (R Core Team, 2013).
We assigned hardcoded allele counts where the alternate allele count of the pool for a particular
variant was assigned to the 𝑛 allele count for which its sequence read data alternate allele count
!

!

was within !" of !" (48 chromosomes per pool). This method gives an approximation of the allele
count for the pool based very simply on the allele count which most closely matches the read
count data. Based on these data, we observed the metric singletons per pool showed serious
outliers. We were concerned this may indicate spurious results resulting from potential problems
during pooling and library preparation. We identified four pools, two case and two control,
greater than the median number of singletons per pool (43) plus the standard deviation (51.25)
(Figure 5). We filtered the four pools before final allele count calling and analysis. We filtered
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variants based on quality score using the R package mclust version 4.2 (Chris Fraley, 2012).
Mclust identified 8 clusters of quality scores for which a division between the first 3 and last 5 at
a quality score of 875 represented an obvious division between low quality and high quality
variants for filtering and maintaining for further analyses (Figure 6). Of the 9928 variants, we
filtered 2736 based on quality score. For each pool we calculated the R2 between allele
frequencies for 2,651 variants imputed from Affymetrix array genotypes using the 1000
Genomes data to the pool allele frequencies based on read count for the variants in the pools. The
median and standard deviation for the R2 values across the 77 pools were 0.9919 and 0.0087. We
excluded four pools, one case and three controls, that were two standard deviations below the
median (Figure 7). We were left with a total 69 pools, 35 case and 34 controls, equivalent to
1,656 samples, 840 cases and 816 controls.

10
0

5

Frequency

15

Singletons Per Pool

0

100

200

300

400

Singleton Count Per Pool

Figure 5: Histogram of sample-wide singletons per pool with pools greater than the median plus standard deviation
marked red.
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Figure 7: Each pool plotted with its imputed genotypes to pooled sequenced genotypes R2 and its proportion of pool with
imputed data. Some samples included in the project did not have GWAS data for imputation. Filtered pools are in red.
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Allele Count Calling
We used a Bayesian method to assign exact allele counts for each variant per pool. We
assigned the probability for the allele count for each pool according to the formula
! !""#"#!!"#$%! !!"#$%!!"!!""#) = !

! !"#$%!!"!!""#! !!""#"#!!"#$%)!!(!!""#"#!!"#$%)
!(!"#$%)

. We calculated the

probability that the read count for reference and alternate alleles in the pool occurred using the
binomial distribution, taking into account the coverage level and number of alternate bases
observed. We assumed there were 0 to 48 alternate alleles in the pool, ! =

!"#$%
!"

, assigning 0 and

48 alleles 0.5% and 99.5% probability, respectively. We used the binomial distribution to
determine the probability that a particular pool has allele counts 0 to 48 given the average minor
allele frequency across all the pools calculated from the alternate and reference read data. We
selected the allele count per variant per pool with the highest probability as the true allele count
and we saved the probabilities for each allele count for simulations during permutation
significance testing. This allele count fine-tuning lowered the excess rate of intrapool multiple
detection for certain rare alleles. For example, for experiment wide doubletons the hardcoded
allele counts yields 103 doubleton variants out of 764 where both alleles are observed in a single
pool. This is expected only 21 times according to the binomial distribution. For the probabilistic
allele counts, intrapool doubletons only occur 44 times representing more than two-fold
reduction in the deviation from expectation. The same trend in improvement is observed with
tripletons (39 to 26, 18.0 expected) and quadrupletons (34 to 24, 15.3 expected) (Figure 8).
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Figure 8: Counts per pool of study-wide doubletons, tripletons and quadrupletons with hardcoded allele counts
(red) and Bayesian allele counts (blue). Bayesian counts are closer to the expected number found per pool (black line)

Statistical Tests
We used variable threshold C-alpha (Neale et al., 2011) and Burden (Price et al., 2010)
testing. The strategy of the C-alpha test is to measure excess binomial variance in the distribution
of allele counts between cases and controls for a set of variants. C-alpha measures general
excesses of risk variation bidirectionally, for protective and damaging alleles. Burden testing
measures excess enrichment of alleles for a set of variants in one direction, either increasing risk
or decreasing risk for the variable in question. C-alpha and Burden tests will both detect excesses
unidirectionally but for bidirectional effects in the same set of variants, the signal will be
cancelled out for Burden testing and will be increased for C-alpha. Variable threshold tests allow
the detection of signals at different MAFs without arbitrarily choosing the threshold for the test.
Not only does the variable threshold test allow for detection of signals, but it also provides
information regarding the MAF of variants contributing to the signal. We assessed the
significance of tests by predicting empirical P-values through permutation of case/control pool
status and a FDR cutoff of 0.2. We performed a variable threshold version of the tests in which,
for every possible allele count in the study under 5% , we calculated a Z-score for all variants at
that allele count threshold and below.
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For C-alpha we calculated the Z-scores at each threshold using the following formula as
outlined in Neale et al., 2011:
! = !/ !
where
!

!=

[ !! − !! !!

!

− !! !! 1 − !! ]

! − !!!

!

− !!! 1 − !!

!!!

and
!"# !

𝑐=

!

!(!)
!!!

!

!(!|!, !! )

!!!

In T, we calculate the variance for each variant where yi is the alternate allele case count for the
i’th variant, ni is the total alternate allele count, and p0 is the proportion of the case samples in
our case pools out of the total number of samples. The variable c standardizes T. Here m(n) is the
number of variants with n alternate allele counts. The sum is taken for each possible case
alternate allele count u.
For Burden tests, we calculated the Z-scores at each threshold using the following
formula as outlined in Price et al., 2010:
!

!

!
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!
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At each threshold, we summed the alternate allele counts in cases C where i indexes variants and
j indexes pools. The symbol ! is the pools case status and ! is the mean case status.
We performed 10,000 permutations of case status per test. For all Z-scores in the test and
permutations at each threshold, we divided by the standard deviation of the permuted Z-scores at
each threshold to standardize the Z-scores across the MAF thresholds. We determined P-values
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by comparing the maximum Z-scores from the 10,000 permutations to the maximum Z-score for
the test. We assessed significance of tests using a FDR cutoff of 0.2.

ENCODE Regions
For DNase I hypersensitive sites, we used DNase-seq Peaks from SK-N-SH_RA and
BE2_C cell lines to represent neuronal positions and from Gliobla, HA-h and NH-A cell lines to
represent glial positions. For transcription factor binding sites (TFBS), we used combined TFBS
SPP-based peaks and TFBS PeakSeq peaks from SH-SY5Y and SK-N-SH_RA to represent
neuronal positions and from Gliobla, U87 and NH-A to represent glial positions. SH-SY5Y data
contained peaks for transcription factor GATA2, and SK-N-SH_RA data contained peaks for
CTCF, p300, RAD21, USF1, and YY1. Gliobla contained peaks for CTCF and POL2, U87
contained peaks for NRSF, and NH-A contained peaks for CTCF. For histone modifications
sites, we used H3K27me3, H3K36me3, and H3K4me3 peaks in SK-N-SH_RA cell lines to
represent neuronal positions and used H3K27ac, H3K27me3, H3K36me3, H3K4me1, and
H3K4me3 peaks in NH-A cell lines to represent glial positions.
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Results

Sequence Data
We collected 1,612,969,337 reads with 166,135,841,711 base calls across all 77 pools,
averaging 20,947,654 reads per pool. An average of 57.1% of the reads were mapped on target
with a range of 45.0% to 62.3% and a standard deviation of 3.3%. On average 44.4% of base
calls were within the target regions. Average per base coverage per individual was 79.2 with a
range of 59.8 to 87.3 and a standard deviation of 5.0. 79.7% of bases within targets had Phred ≥
20 and the average coverage for Phred ≥ 20 was 59.4 (44.6 to 69.2 range, 3.7 standard
deviation). 98.4% of the target bases had at least 20x average coverage per sample.
We called 9,928 variants using CRISP (Bansal, 2010). After filtering pools based on
excess singleton detection and poor correlation with known genotypes for the pool, 7,029
variants and 1,656 samples (840 cases and 816 controls) remained. We removed 426 variants for
low quality scores (see methods) and an additional 24 variants that fell below our inclusion
threshold of 20x coverage for a total of 6,579 passing variants. Finally, we only tested variants
with MAFs 5% or lower, excluding an additional 1,129 variants. Of the 5,450 remaining variants
2,944 were singletons that are not tested in C-alpha because they do no provide a deviation from
an expected distribution, as random chance will always have a singleton allele in either a case or
a control sample. This left 5,450 variants for Burden testing (Price et al., 2010) and 2,506
variants for C-alpha testing (Neale et al., 2011). There were 348 indels called out of the 5,450
variants. For doubletons and greater 182 variants of 2,506 were indels. Of the 6,579 variants that
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passed filtering 3,881 were novel and 2,698 were previously observed. Figure 9 shows the
distribution of variants by MAF.
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Figure 9: Histogram of MAF in variants that passed all filtering and that are less than 5% MAF.

Summary
Our testing strategy involved applying the Burden and C-alpha pooled association tests to
sets of the variants that passed filtering. We selected the variant sets to probe and clarify the role
of rare variation in schizophrenia. Starting from the most general set, every variant in the study
less than 5% MAF, we then narrowed the focus to sets of study-wide coding and non-coding
variants. We used conservation scores to group non-coding variants into low conservation and
high conservation positions to better understand the signal in the non-coding regions and we also
used conservation scores to compare the sets of coding and non-coding variants with the most
highly conserved base positions. We tested variants grouped into sets by ENCODE (Rosenbloom
et al., 2013) functional elements. Finally, to detect the influence of rare variation specific to a
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particular locus, we tested locus variant sets individually. The Burden pooled association test
measures an aggregation of excess variants with unidirectional effects, either protective or
damaging (see Methods). C-alpha measures an aggregation of excess variants in the test with
bidirectional effects, both protective and damaging. These tests are complimentary in that a
Burden tests indicates the general direction of effect for the excess risk-altering variation in the
set, but will not detect an even mixture of excess protective and damaging variation while Calpha will detect the mixture, but not indicate a general direction of effect for excess risk-altering
variation. No Burden tests were significant at 20% FDR so all results that follow refer to C-alpha
results. The results for all tests are summarized in Table 2.
Table 2: Test results. Tests with a (B) indicate the test was a Burden test otherwise it is a C-alpha test.

General Tests
Entire Target
Entire Target (B)
Non-coding
Non-coding (B)
Coding
Coding (B)
High Impact
High Impact (B)
Constrained
Constrained (B)

MAF
0.09%
0.12%
0.09%
0.12%
0.09%
2.17%
0.06%
0.33%
4.20%
1.99%

Allele
Count
3
4
3
4
3
72
2
11
139
66

Locus Tests
MIR137
MIR137 (B)
ITIH3/4
ITIH3/4 (B)
TRIM26
TRIM26 (B)
CSMD1
CSMD1 (B)
ANK3
ANK3 (B)
CNNM2-NT5C2

2.90%
0.12%
0.72%
0.27%
1.42%
0.06%
1.45%
0.09%
0.09%
4.26%
2.20%

96
4
24
9
47
2
48
3
3
141
73
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Variants ≤
Threshold
986
4072
828
3424
158
823
8
89
1277
2798

Zmax
4.31
-2.78
3.89
-2.99
3.32
-1.48
1.36
-0.77
3.28
-1.32

P-value
0.011
0.519
0.024
0.285
0.071
1.000
0.489
1.000
0.089
1.000

q-value
0.111
0.601
0.111
0.453
0.182
0.744
0.587
0.744
0.205
0.744

116
176
94
226
38
30
669
1327
143
787
143

1.59
-1.60
2.49
-1.62
2.15
-1.75
3.44
-1.45
3.22
-1.85
1.94

0.476
0.995
0.188
0.977
0.128
0.752
0.040
1.000
0.062
0.989
0.421

0.580
0.743
0.353
0.739
0.271
0.686
0.142
0.744
0.168
0.742
0.550

CNNM2-NT5C2 (B)
STT3A
STT3A (B)
CACNA1C
CACNA1C (B)
TCF4
TCF4 (B)

1.06%
2.11%
2.11%
0.21%
0.09%
0.30%
4.23%

35
70
70
7
3
10
140

308
20
56
232
577
299
1017

1.14
2.54
-0.91
1.44
-2.11
4.06
2.29

1.000
0.176
0.998
0.608
0.944
0.023
0.885

0.744
0.338
0.743
0.638
0.733
0.111
0.720

ENCODE Elements Tests
DNase glial
DNase glial (B)
DNase neuronal
DNase neuronal (B)
Histone glial
Histone glial (B)
Histone neuronal
Histone neuronal (B)
TFBS glial
TFBS glial (B)
TFBS neuronal
TFBS neuronal (B)

0.06%
3.11%
4.20%
0.09%
2.90%
0.06%
0.09%
2.32%
2.39%
2.39%
2.87%
0.03%

2
103
139
3
96
2
3
77
79
79
95
1

61
386
118
197
586
880
135
657
104
235
231
298

2.28
-2.70
3.96
-1.94
4.15
-2.36
3.70
-1.41
2.26
-2.02
4.26
1.50

0.322
0.246
0.031
0.880
0.022
0.836
0.048
1.000
0.266
0.808
0.015
1.000

0.483
0.417
0.127
0.719
0.111
0.708
0.153
0.744
0.436
0.701
0.111
0.744

Conservation Median Split Tests
phastCons high conservation
phastCons high conservation (B)
phastCons low conservation
phastCons low conservation (B)
phyloP high conservation
phyloP high conservation (B)
phyloP low conservation
phyloP low conservation (B)
SiPhy-pi high conservation
SiPhy-pi high conservation (B)
SiPhy-pi low conservation
SiPhy-pi low conservation (B)

1.12%
0.21%
3.05%
0.12%
0.06%
0.21%
3.14%
0.12%
0.06%
0.12%
0.09%
0.12%

37
7
101
4
2
7
104
4
2
4
3
4

855
1849
994
1710
297
1855
1009
1697
286
1715
438
1709

3.17
-1.11
4.07
-2.97
3.41
-1.58
4.11
-2.86
3.37
-1.28
4.28
-3.24

0.105
1.000
0.013
0.285
0.054
1.000
0.017
0.387
0.058
1.000
0.010
0.110

0.234
0.744
0.111
0.453
0.160
0.744
0.111
0.529
0.164
0.744
0.111
0.242

Functional Domain Tests
CUB-CSMD1
CUB-CSMD1 (B)
Sushi-CSMD1
Sushi-CSMD1 (B)

1.39%
0.66%
0.09%
0.12%

46
22
3
4

118
304
8
53

4.86
1.43
2.34
1.26

0.005
0.999
0.227
0.988

0.111
0.744
0.397
0.741

High Conservation Tests
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phyloP > 2
phyloP > 2 (B)
phyloP > 2 coding
phyloP > 2 coding (B)
phyloP > 2 non-coding
phyloP > 2 non-coding (B)

1.12%
0.06%
0.06%
0.06%
1.12%
0.06%

37
2
2
2
37
2

186
403
15
135
129
268

3.44
-2.36
2.93
-2.19
4.09
-1.19

0.050
0.582
0.088
0.509
0.019
1.000

0.156
0.628
0.204
0.596
0.111
0.744

Study-Wide Tests
Our first test was an analysis of all 2506 variants detected in our entire target set. At a
threshold of ≤ 0.09% MAF, in our study size representing variants with 2 or 3 alternate alleles
detected in the sample as a whole, we observe a significant excess of variance in the distribution
of alleles between cases and controls compared to random expectation because these alleles are
uniquely or preferentially represented in one phenotypic group or the other (P = 0.011, q =
0.111, Figure 10). At this low MAF, alleles contributing to signal are uniquely present in cases or
controls, for example both doubleton alleles being seen in cases or all three tripleton alleles being
seen in controls.
We were interested in comparing independent contributions from coding and non-coding
sequences, so we split the variants into a non-coding variants group and an exon and UTR
variants group for further testing. Testing each set independently, we again detect peak signals at
≤ 0.09% MAF in both non-coding (P = 0.024, q = 0.111) and coding (P = 0.071, q = 0.182)
subsets (Figure 10). For both our coding and non-coding variants we observed very rare variation
driving the signal of excess unequal case/control allele distribution.
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Figure 10: Z-scores at each MAF threshold for all, coding plus UTRs and non-coding variation. For each MAF
threshold we calculate a Z-score for all variants at the threshold and below. Each point on the line represents the Z-score
for all variants at that MAF and below. The horizontal dotted lines are the levels for which only 5% of the permutation Zmax scores are greater than or equal to for the test.

Conservation
In addition to the peak signal at ≤ 0.09% MAF that we formally tested, the graph of noncoding variant results in Figure 10 also suggests that non-coding alleles with higher MAF from
3.14% to 4.05% are also differentially distributed between cases and controls. We examined
these signals further by dividing the non-coding variants into more and less highly conserved sets
using a median split for each of three different measures of conservation, phyloP, SiPhy-pi, and
phastCons (Garber et al., 2009; Pollard, Hubisz, Rosenbloom, & Siepel, 2010). Scores had been
generated using the three methods from Multiz alignments!(Blanchette et al., 2004) from 46
species of the placental mammals phylogenetic tree (Murphy et al., 2001). PhyloP and SiPhy-pi
measure conservation at a single base while phastCons incorporates flanking bases. Unlike
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phastCons and phyloP, SiPhy-pi allows for detection of biased substitution patterns. The
consideration of the flanking regions in phastCons makes it useful for identifying regions of
conservation, instead of positions of conservation. The consideration of biased substitution
patterns in SiPhy-pi makes it useful for such special cases. We consider phyloP to be the most
general measurement of conservation because it measures conservation at a single base and
considers any base changes across species as evidence for lower conservation. We examined the
similarity of conservation scores, and since the phastCons measure generally takes values of 0 or
1, our comparison was limited to phyloP and SiPhy-pi scores. PhyloP and SiPhy-pi scores show
a reasonable degree of correlation (0.548, Figure 11). Points lying off the diagonal are due to the
biased substitution detection in SiPhy-pi for certain sites that increases the conservation score
compared to phyloP, which does not detect these patterns.
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Figure 11: Scatter plot of phyloP scores vs. SiPhy-pi scores for all 6,579 post-filtering variants. The correlation between
the scores is 0.548. The fanning off the diagonal trend is due to detection of biased substitution patterns using SiPhy-pi.
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For the phyloP (Figure 12) high and low conservation split, we observe a significant
excess of variance in the distribution of alleles at 0.06% MAF (P = 0.054, q = 0.160) for the
highly conserved positions and ≤ 3.14% MAF (P = 0.017 q = 0.111) for the less conserved
positions. The less conserved base position variant set shows a clear excess of signal coming
from higher MAF compared to the more conserved base position variant set which has a peak
signal from doubleton variants.
Variants at 0.06% MAF (P = 0.058, q = 0.164) at highly conserved positions and ≤
0.09% MAF for less conserved positions (P = 0.010, q = 0.111), defined by SiPhy-pi (Figure
13), were also unequally distributed between cases and controls. While still having a rarer signal
in more conserved positions, the SiPhy-pi score MAF difference is not as large as seen in
phyloP.
Variants ≤ 3.05% MAF in less conserved positions as defined by phastCons (P = 0.013, q
= 0.111) were unequally distributed between cases and controls (Figure 14). Variants in highly
conserved phastCons positions had a similar pattern to phyloP with a lower MAF peak signal
(1.12%), but this test was not significant. Although the test was not significant, the lower MAF
peak signal in more conserved positions still matched the patterns seen in phyloP and SiPhy-pi.
Across the three measures of conservation, we observe a clear pattern of significant
differences in allelic distributions between cases and controls coming from higher frequency
variants at less conserved positions. This is strongest and most evident in the most general
conservation measure, phyloP. For the variant sets of the more conserved positions, the signal is
predominately from very rare doubleton and tripleton variants using phyloP and doubleton
variants using SiPhy-pi.
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Figure 12: Z-scores for high and low phyloP scores
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Figure 13: Z-scores for high and low SiPhy-pi scores
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Figure 14: Z-scores for high and low phastCons scores

Narrowing the analysis further to consider only variants in the positions defined as
constrained in the 29 mammal comparison (Lindblad-Toh et al., 2011), which includes all coding
sequences, we detected a near significant difference (q = 0.205) in the distribution of alleles
between cases and controls for ≤ 4.20% MAF (Figure 15). This result is weak support for excess
unequal case/control allele distribution from much more common variation contributes to the
signal from constrained regions.
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Figure 15: Z-scores for all constrained, coding and UTR variations

High Impact and High Conservation
We also tested frameshift, splice site, nonsense variants in addition to missense variants
predicted to be damaging by Condel (Gonzalez-Perez & Lopez-Bigas, 2011) as a high impact
variation group. The test was not significant possibly due to the low number of variants available
to test with only 8 doubleton variants contributing to its peak Z-score. We pursued a different
strategy to select potentially high impact variation by testing coding and non-coding variants
with a base position phyloP score above 2, which indicates a less than 1% chance that the base
would appear as conserved by chance. This strategy allows comparison of coding and noncoding variants at equally high levels of conservation. The distribution of variant phyloP scores
is shown in Figure 16, with line indicating a phyloP score of 2. We observe more variants at
these highly conserved positions in non-coding regions (390) than in coding regions or UTRs
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(193). For all variants in this category we observed a significant signal ≤ 1.12% MAF (P =
0.050, q = 0.156). When splitting these variants into coding and non-coding groups we observed
a significant signal at ≤ 1.12% MAF (P = 0.019, q = 0.111) and nonsignificant peak signal (q =
0.204) at 0.06% MAF respectively (Figure 17). The high conservation coding test only included
15 doubleton variants contributing to its peak Z-score so the test is relatively underpowered.
While we observed that rare variation contributes the predominant signal for the more conserved
half of non-coding variation, the non-coding variants in the most highly conserved positions
yield a peak signal at a higher MAF. The higher MAF of the C-alpha signal peak for the most
highly conserved non-coding positions is not consistent with the very rare peak for the more
conserved half of non-coding positions. An explanation for this may be that the highly conserved
set only represents a small subset of the more conserved half of non-coding positions (151
variants out of 1039) and therefore is less stable of a signal. We find the non-coding variants at
highly conserved positions have more significant differences in allelic case/control distribution at
higher MAFs than in coding variants at equivalently conserved positions. It is possible that the
conservation of these positions in non-coding sequences does not reflect the same level of
importance as in coding sequences, allowing risk-altering variants for schizophrenia to be
maintained in the population at a higher MAF and lower effect size at these sites.
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Figure 16: PhyloP base scores for variation in coding regions and UTRs and variation in non-coding regions. The dotted
vertical line marks a phyloP score of 2. While the proportion of variation in coding regions and UTRs at bases phyloP > 2
(0.194) is higher than the proportion found in non-coding regions (0.070), the number of non-coding variants at bases
with phyloP > 2 (390) is greater than the number found in coding regions and UTRs (193).
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Figure 17: Z-scores for all highly conserved (phyloP > 2) also showing the split into coding and non-coding variation.

ENCODE Regions
We also assigned the variants to DNase I hypersensitive sites, TFBS, and histone
modification sites found to be active in neuronal and glial cells in the ENCODE project. Details
on how we defined ENCODE test regions are in the methods section.
DNase I hypersensitive sites had a significant excess unequal case/control allele
distribution (≤ 4.20% MAF, P = 0.031, q = 0.127) but DNase I hypersensitive regions in glial
cells did not (Figure 18). The excess of unequal distribution of case/control alleles was
predominantly in more common variants for the DNase I neuronal variant set.
Transcription factor binding sites had a significant excess unequal case/control allele
distribution for neuronal cell regions (≤ 2.87% MAF, P = 0.015 q = 0.111) (Figure 19) but did
not for glial cell regions. For variants in the neuronal cell TFBS the excess in unequal
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distribution of case/control alleles was at a lower, but still relatively common, MAF than in
DNase I hypersensitive sites.
We observed significant excess unequal case/control allele distribution for histone
modification sites observed in neuronal cells (≤ 0.09% MAF, P = 0.048, q = 0.153) and glial
cells (≤ 2.90% MAF, P = 0.022, q = 0.111) (Figure 20). The signal of excess unequal distribution
of case/control alleles is very different in neuronal histone modification sites compared to glial
histone modification sites, with the former being from rare variants (case and control, only
doubletons and tripletons). The results of the tested ENCODE regions require careful
interpretation. We include methylated histone markers that activate transcription, H3K4me1,
H3K4me3, and H3K36me3, and repress transcription, H3K27me3. For acetylation, we include
H3K27ac, which increases openness of chromatin. C-alpha testing is bidirectional, allowing for
detection of bidirectional signals as may be seen in a combination of transcription activating and
repressing histone modification sites. In histone modification sites from glial cell lines we
observe more common variation in the ≤ 2.90% MAF range contributing to excess unequal
distribution of case/control alleles, but for neuronal cell line sites this signal comes from very
rare variation ≤ 0.09% MAF. For our geneset, variants in neuronal histone modification sites
may be under heavier selection than variants in glial histone modification sites.
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Figure 18: Z-scores for DNase I hypersensitive sites from neuronal cell lines

4

Z−score

3

2

1

0
0

1

2

3

4

MAF (%)

Figure 19: Z-scores for transcription factor binding sites from neuronal cell lines
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Figure 20: Z-scores for histone modification sites from neuronal and glial cells

Locus Tests
We further examined each of the 9 loci separately. We observed significant results for
three individual loci, ANK3, a joint schizophrenia and bipolar risk locus that encodes the voltagegated sodium channel associated Ankyrin G, the miR-137 regulated transcription factor TCF4,
and complement control related gene CSMD1. ANK3 (Figure 21) had the lowest allele frequency
threshold for its C-alpha signal (≤ 0.09% MAF, P = 0.062, q = 0.168). The peak C-alpha signal
for TCF4 (Figure 22) was significant at ≤ 0.30% MAF (P = 0.023, q = 0.111) and the peak Calpha signal for CSMD1 (Figure 23) was significant at ≤ 1.45% MAF (P = 0.040, q = 0.142).
CSMD1 has an interesting property in that it consists primarily of two repeating functional
domains, the CUB domain and the Sushi domain. We tested the variants in these domains
separately and observed a significant excess unequal distribution of case/control alleles in the
CUB domains (≤ 1.39% MAF, P = 0.005, q = 0.111) but not the Sushi domains. The CUB
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domains of CSMD1 had the most significant P-value from the study. The Sushi domains had
relatively few variants (28) in the test set which may have contributed to the low signal. CSMD1
is an interesting gene because of its role in cancer and inflammation. Expression of CSMD1
mRNA cloned in rats is primarily found in developing CNS and epithelial tissues(Kraus et al.,
2006). The CSMD1 protein was detected in the neuronal growth cone in developing fetal rat
brains.
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Figure 21: Z-scores for ANK3
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Figure 22: Z-scores for TCF4
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Figure 23: Z-score for CSMD1 and its functional domains, CUB and Sushi
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Discussion

Summary
Our results show that rare variation influencing schizophrenia risk is not limited to the
coding exons and UTRs included in current exome sequencing studies. The high levels of
conservation across species in these select non-coding positions increase the chance that changes
to the sequence affect gene function and disease risk. It is significant that these signals were also
observed in regions selected based on common variant associations from GWAS. As in IBD
(Rivas et al., 2011) we observe rare variation in the loci selected through common variation
association, independently supporting the involvement of these loci in schizophrenia. More loci
implicated in recent GWAS (Ripke et al., 2013) (S. W. G. o. t. P. G. Consortium, 2014) should
be explored for causal rare variation to help elucidate the mechanism by which these loci affect
disease and to assess the additional impact of rare variation.

Rare Non-coding Variation in Disease
In our study 84% of the variation < 0.1% MAF range contributing to the signal was in
non-coding regions and the signal was maintained when coding and non-coding variants were
tested separately. The addition of non-coding sequence could greatly improve the quality and
amount of information obtained from sequencing studies of all diseases. Exome studies could be
expanded for targeted deep sequencing in non-coding functional and conserved sequences
beyond the exome, until whole genome deep sequencing for large sample sizes is cost-effective.

52

The observation of rare non-coding variation is not unique to our study. Sequencing of the IL4
locus in 72 African American (AA) asthma cases and 70 AA controls revealed an excess of
private non-coding rare variants in cases (Haller, Torgerson, Ober, & Thompson, 2009). The
authors suggest these rare variants cannot be reliably imputed and therefore sequencing of noncoding regions is important for identifying rare genetic variants contributing to disease. A study
of 100 genes implicated in asthma using 450 cases and 515 controls found IL12RB1 to be a
susceptibility locus with predominately non-coding variant signals in both AA and European
Americans (EA) (Torgerson et al., 2012). Limited work has been done on non-coding rare
variation is schizophrenia. A study sequencing 27 kb from six schizophrenia candidate genes,
AKT1, BDNF, DRD3, DTNBP1, and NRG1, found an excess of rare non-coding variants in 37
cases compared to 25 controls (Winantea et al., 2006). The researchers determined the
enrichment by calculating Tajima’s D-value for the cases and the controls. A small Tajima’s Dvalue in cases compared to controls indicated an excess of rare variants in the case sample.
Our work is the first large study discovering influence of non-coding rare variants in
several loci for schizophrenia. The evidence from asthma, an autoimmune disorder, supports our
finding in schizophrenia, a disease for which the immune system is also implicated.

Locus Tests
The loci that we found significantly associated with schizophrenia were ANK3, TCF4 and
CSMD1. ANK3 was first identified as a bipolar disorder locus in a GWAS of 4,387 cases and
6,209 controls (Ferreira et al., 2008). The PGC-1 study was the first to observe a joint association
for combined bipolar disorder cases and schizophrenia cases compared to controls (Ripke S,
2011). In a study of 516 Han Chinese schizophrenia cases and 400 controls, ANK3 was
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implicated as an independent schizophrenia risk locus (Yuan et al., 2012). More recently, coding
variation in ANK3 has been associated with autism (Bi et al., 2012).
Several studies of ANK3 and its protein product Ankyrin-G and their effect on
neurodevelopment and cognitive performance have been published. Ankyrin-G is a scaffolding
protein that localizes to the axon initial segment and nodes of Ranvier of neurons (Kordeli,
Lambert, & Bennett, 1995). Knockdown of ANK3 was found to increase β-catenin in the nucleus,
causing an increase in neural progenitor proliferation (Durak et al., 2014). The mechanism
suggested for the increase in β-catenin is that functional ankyrin-G interacts with E-cadherin and
Wnt. One study found damaging mutations in the ANK3 gene in patients with severe cognitive
deficits (Iqbal et al., 2013). The authors found all isoforms of ANK3 disrupted by a balanced
translocation in one patient with autism, attention deficit hyperactivity disorder (ADHD),
sleeping problems, and borderline intelligence. They also found a frameshift mutation in the
longest isoform segregating in a family with moderate intellectual disability. Reasoning that
memory deficits are common to disorders such as intellectual disability, autism and ADHD, the
authors disrupted Ank2, the closest homolog to human ANK3 in Drosophila. They observed a
significant reduction of short-term memory in the flies. The authors observed normal learning
and other behaviors, and concluded that Ank2 was crucial for properly functioning memory in
Drosophila. A study of cognitive deficits in 173 patients with first episode psychosis found
association of a common ANK3 allele (allele G of rs1938526) with lower cognitive performance,
verbal memory, working memory and attention (Cassidy et al., 2014). The authors also observed
an association between this allele and cortical thinning. An additional study of 163 patients with
first-episode schizophrenia and 42 controls found association of a common ANK3 allele (allele T
of rs10994336) with lower accuracy and longer reaction time in a 2-back test, where the
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participant must log items flashed on a screen in addition to the 2 items before (Zhang et al.,
2014). Our study is the first to implicate rare variation in ANK3 as a risk factor for schizophrenia.
TCF4 was first identified as a schizophrenia risk factor in an early GWAS (Stefansson et
al., 2009). It is a basic Helix-Loop-Helix transcription factor found through knockdown
experiments to be involved in cell survival, epithelial to mesenchymal transition, and
neurodevelopment (Forrest, Waite, Martin-Rendon, & Blake, 2013). It has been identified as a
susceptibility locus for multiple disorders, with common variants identified impacting Fuch’s
endothelial corneal dystrophy, primary sclerosing cholangitis and, as previously mentioned,
schizophrenia (Forrest, Hill, Quantock, Martin-Rendon, & Blake, 2014). Our study is the first to
observe rare variation in TCF4 associated with schizophrenia. Private frameshift, nonsense,
splice site and missense variants and deletions (CNVs partially covering the gene or completely
covering the gene) of TCF4 have been found to cause Pitt-Hopkins syndrome (Peippo &
Ignatius, 2012), a syndrome characterized by intellectual disability and developmental delay. A
study of smokers and never-smokers taken randomly from the German population found that
smokers with the rs9960767 risk allele had reduced sensory gating, measured by P50 suppression
(Quednow et al., 2012). In patients with first episode psychosis, the rs9960767 risk allele has
also been associated with lower performance in the Reasoning/Problem-Solving domain of the
WAIS-III and Trail Making Test B (Albanna et al., 2014; Reitan, 1992). There is also evidence
for correlation of the risk allele in schizophrenia cases with improved cognitive performance. In
one study schizophrenia cases with the rs9960767 risk allele performed better on the Rey
Auditory Verbal Learning Test (Helmstaedter, 2001), which measures verbal declarative
memory (Lennertz et al., 2011). In a Han Chinese sample, schizophrenia cases homozygous for
the rs2958182 risk allele performed better on cognitive tasks compared to cases with the non-risk
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allele (Zhu et al., 2013). Han Chinese controls homozygous for the rs2958182 risk allele
performed worse on cognitive tasks (Zhu et al., 2013). The literature on cognition, schizophrenia,
and common variant TCF4 loci has been mixed, with some positive effects and some negative
effects correlated with the risk alleles for schizophrenia patients.
Our significant TCF4 C-alpha test shows that rare variation has a bidirectional effect.
Some variants are protective, decreasing schizophrenia risk, and some variants are damaging,
increasing schizophrenia risk. This is supported by the biology of basic Helix-Loop-Helix
transcription factors, which may act as transcriptional repressors or activators (Quednow,
Brzozka, & Rossner, 2014). In Forrest et al., 2013, TCF4 knockdown caused increased
expression for 494 genes and decreased expression for 710 genes (Forrest et al., 2013). With
such a great number of upregulated and downregulated genes, damaging variants in TCF4 seem
likely to perturb regulation of a large number of individual loci with potentially significant
impact on neurodevelopment and later function. Such focal changes in a single transcription
factor gene could potentially mimic and interact with the effects of numerous variants from other
loci on schizophrenia risk, given the strong support for a highly polygenic and distributed genetic
structure.
A study of 512 schizophrenia cases and 270 controls searched for causal rare variation in
a small, ultraconserved non-coding 227 bp region of TCF4 with evidence for enhancer activity
(UC435) (Gonzalez-Penas et al., 2014). The researchers did not find any variants in UC435. In
our 840 case and 816 control sample we found only one singleton in UC435, in a case sample at
chr18:53089932 (novel A allele, G reference). Our TCF4 locus test included many other noncoding regions and our results suggest an aggregation of low frequency TCF4 variation
impacting schizophrenia risk.
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CSMD1 is a transmembrane protein, and contains repeating and alternating CUB and
Sushi (complement control protein or CCP) domains. Sushi domains are involved in complement
inhibition for the classical and lectin pathways of the complement system. The complement
system is the immune system’s first line defense against foreign antigens. The 15 Sushi tandem
repeat inhibits complement deposition on eukaryotic cell surfaces (Escudero-Esparza,
Kalchishkova, Kurbasic, Jiang, & Blom, 2013). The CUB domain is a 110-residue domain
structure, composed of a β-sandwich fold. Many proteins have CUB domains with a Ca2+
binding site, including CSMD1 (Gaboriaud et al., 2011).
CSMD1 is a tumor suppressor gene implicated in multiple cancers, including squamous
cell carcinoma, colorectal cancer, melanoma, lung, head and neck, and breast cancer. One study
showed copy number losses in CSMD1 in head and neck squamous cell carcinoma, cutaneous
squamous cell carcinoma, cutaneous basal cell carcinoma, lung and breast cancers (Ma et al.,
2009). Another study showed that 87% of squamous cell carcinoma cell lines had increased
methylation upstream of the CSMD1 transcription start site, associated with gene silencing,
compared to normal upper aerodigestive epithelial cells (Richter, Tong, & Scholnick, 2005). A
study has also found low levels of CSMD1 expression in melanoma (Tang, Wang, Guo, Han, &
Wang, 2012). Somatic nonsynonmous mutations have been observed in late stage colorectal
cancer (Farrell et al., 2008) and in colorectal cancer diagnosed at an early age (Shull et al., 2013),
indicating a role for CSMD1 the development of aggressive, metastatic disease.
In addition to schizophrenia and cancer, CSMD1 has been implicated in bipolar disorder
through GWAS (Sklar et al., 2008) (Baum et al., 2008) (W. Xu et al., 2014) and autism through
CNVs (Glancy et al., 2009) and exome sequencing in families (Cukier et al., 2014). Involvement
in neuropsychiatric disorders is supported by the observation that the CSMD1 gene cloned in rats
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was expressed primarily in the developing CNS and epithelial tissues, and its protein was
enriched in fetal rat nerve growth cones (Kraus et al., 2006).
The CSMD1 risk variant implicated in schizophrenia (rs10503253) has been studied for
impact on several neurocognitive effects. A study of 1,149 healthy Greek Caucasian males found
additive effects of the risk allele for poorer general cognitive ability (IQ), strategy formation,
spatial and visual working memory, set shifting, target detection, and planning for problem
solving (Koiliari et al., 2014). Similar results were found in a study of Irish and German
schizophrenia cases and controls with the risk allele being associated with poorer IQ and
memory function (Donohoe et al., 2013). With evidence for the role of CSMD1 in
neurodevelopment, and its impact on cognitive abilities, investigators used MRI and fMRI to
measure the effect of the rs10503253 genotype on grey and white matter volume and activity
during a spatial working memory task (Rose et al., 2013). The authors found that the risk allele
was significantly associated with reduced cortical activations in the right middle occipital gyrus,
a region involved in spatial working memory. No structural differences in brain volume were
found based on genotype.
CSMD1 rare variation has not been strongly implicated in neuropsychiatric disorders.
There is no evidence of CSMD1 rare variation in bipolar disorder and there is only weak
evidence of CSMD1 rare variation in autism. CSMD1 variants were observed in two separate
autism families in a 40 family study (Cukier et al., 2014). Also, unlike TCF4’s association with
Pitt-Hopkins syndrome, CSMD1 rare variation is not associated with any syndromes. The only
strong evidence for rare variation in CSMD1 impacting disease has been somatic mutations in
cancer.
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The CSMD1 signal we observed differs from both ANK3 and TCF4 in that it is a less rare
signal, with a signal maximizing when alleles up to 1.45% MAF are included in the test. This
result is consistent with the lack of strong association of other neuropsychiatric disorders with
rare variation in CSMD1. Even though the variation in CSMD1 driving the signal in our study is
not very rare, our results support association of the gene with schizophrenia at a lower MAF than
PGC-1 (≤1.45% compared to 19%). Our observation of a signal coming specifically from the
CUB domain is a first for schizophrenia. No functional work has been done on the CUB domain
or CSMD1 in schizophrenia, but based on the literature and our results it may be a promising
candidate gene and functional domain.

Functional Class Tests
In our study, we found variations within ENCODE functional elements from neuronal
and glial cell lines to be associated with schizophrenia. We tested functional elements active in
neuronal cell lines because neurons are the primary cells involved in cognition and central
nervous system (CNS) function. Our analysis of functional elements active in neuronal cell lines
shows that variation in transcription factor binding sites, DNase I hypersensitive sites, and
especially rare variation from histone modification sites influences schizophrenia risk.
We tested functional elements active in glial cell lines because glia support neurons and
the three major classes of glial cells, oligodendrocytes, microglia and astrocytes, have been
implicated in schizophrenia (Goudriaan et al., 2013) (Frick, Williams, & Pittenger, 2013).
Dysfunction in oligodendrocytes, glial cells that produce the myelin in the nervous system, has
been shown to impact synaptic function and white matter integrity in the brain (Takahashi,
Sakurai, Davis, & Buxbaum, 2011) and an analysis of common variant p-values from the PGC-1
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schizophrenia study (Ripke S, 2011) found the oligodendrocytic gene set pathway associated
with schizophrenia (Duncan et al., 2014). Variation in oligodendrocyte specific genes involved
in myelin production affects cognitive performance and the integrity of white matter tracts
(Voineskos et al., 2013). Microglia are macrophages in the CNS involved in innate immunity.
There is evidence that microglia play a role in schizophrenia through neuroinflammation (Monji
et al., 2013). Astrocytes support the nervous system in several ways, including by providing
structural and nutritional support for neurons and aiding synaptic function (Takahashi & Sakurai,
2013). One study observed a significant decrease in astrocyte density in the cingulate gray
matter, cingulate white matter and midline of the corpus callosum in schizophrenia patients
compared to controls (Williams et al., 2013). Loss of function in astrocytic receptors and gap
junctions of astrocytes may contribute to cognitive impairment in schizophrenia. (Mitterauer,
2011).
The data we used in our glial DNase I hypersensitive sites, transcription factor binding
sites, and histone modification sites analyses were all from astrocyte-derived cell lines: Gliobla,
HA-h, NH-A, and U87 (Project, 2014). At the time of this study, ENCODE data for microglia
and oligodendrocytes were unavailable. We also found damaging and protective variation (Calpha test) in histone modification sites active in the cell lines. Literature supports the effect of
epigenetic modulation of histone deacetylase inhibitors on schizophrenia (Cha, Kudlow,
Baskaran, Mansur, & McIntyre, 2014) and we included acetylated histone regions in our glial
histone modification test. H3K4me3, a trimethylation of histone H3 at lysine 4 we included in
our glial and neuronal histone modification test, is an active mark for transcription and is
implicated in increased expression of synapsin genes in bipolar disorder and major depression
(Cruceanu et al., 2013). The signal in histone modification sites is very different in neuronal cell
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line regions compared to glial cell line regions. The signal from neuronal cell line regions is
driven by much rarer alleles (≤ 0.09% MAF) than the signal from glial cell line regions (≤ 2.90%
MAF), possibly indicating that variation in neuronal cell line regions is under heavier selection
pressure.

Limitations
The results of this study must be interpreted with several limitations. We performed
sequencing in pools of 24 cases or 24 controls. This method is efficient, but did not allow us to
incorporate LD into our analysis. We used permutation testing to compensate for the effects of
LD on the test statistic. Pooled sequencing may also introduce some error in allele count calling.
Our careful consideration of concentration while pooling, careful quality control, and improved
probabilistic allele count calling mitigates this risk. Also, we were not able to include every
constrained site within our target region due to the 500kb limit using the specific capture
approach we chose, but our target and bait design did include 84.5% of all constrained sites at
10% FDR across 29 mammals (Lindblad-Toh et al., 2011) within our target intervals.

Future Studies
Although pooled association tests can identify associated loci, future studies should use a
much larger sample size, probably on the order of the largest GWAS size, to find single rare
variant associations. As our data show, future sequencing studies should include non-coding
regions because they may contain useful data. Lower capture and library preparation costs will
make individual sample sequencing more affordable. Future studies should consider using
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individual sample sequencing to eliminate the limitations of pooled sequencing studies discussed
above. The ultimate future study will use low cost, individual, whole genome sequencing.
There are many influences on the heritability of schizophrenia that remain unexplained
and that may be uncovered by increasing sample size and amount of the genome sequenced. The
discovery of individual rare variants associated with schizophrenia will promote a new series of
functional studies to elucidate the mechanism by which the variants affect schizophrenia risk.
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